Clinical Evaluation of Safety and Efficacy of Radio-Frequency Assisted Lipolysis (RFAL) of Breast Envelope and Nipple-Areolar Complex (NAC) Position
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Measurements of Distance (cm) Between Breast Area Reference Points (Nipple to Nipple)
研究概览
简要总结
This single center clinical study is intended to determine the safety and efficacy of using Radiofrequency (RF) energy for minimally invasive breast lift procedure.
详细描述
The purpose of this study is to evaluate the safety and efficacy of RFAL for the Breast Envelope and Nipple-Areolar Complex (NAC) Position as measured by Vectra 3D circumferential imaging system (Canfield, NJ)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Informed consent agreement signed by the subject.
- •Healthy females 21 to 60 years of age.
- •Presence of grade I-III Breast Ptosis, mastopexy with history of breast augmentation, correction of asymmetry, mastopexy alone, mastopexy following implant removal and modest breast reduction in combination with or without lipoaspiration.
- •Post-menopausal or surgically sterilized or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).
- •Willingness to follow the treatment and follow-up schedule and the post-treatment care.
- •All participants must have a recorded mammogram before the beginning of the study.
排除标准
- •Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
- •Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance.
- •Current or history of skin cancer (remission of 5 years), or current condition of any other type of cancer, or pre-malignant moles.
- •Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
- •History of bleeding coagulopathies or use of anticoagulants in the last 2 weeks.
- •Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.
- •Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
- •Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
- •History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
- •Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
- •Significant systemic illness or occult systemic illness.
- •Illness, infection or skin diseases localized in area of treatment.
- •Other therapies or medication which may interfere with treatment.
- •Breastfeeding, pregnant, or planning to become pregnant during the study.
- •Allergy to lidocaine or other anaesthesia.
- •Recent surgery in treatment area within the past 6 months.
- •Participation in a study of another device or drug within 3 months prior to enrolment or during this study.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the patient to participate in this study.
- •As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient.
结局指标
主要结局
Measurements of Distance (cm) Between Breast Area Reference Points (Nipple to Nipple)
时间窗: 12 months
Regular and 3D Vectra photos will be taken at all time points. Additional evaluation of changes in breast shape, including upper pole fullness, breast projection, and bottoming out will be assessed by static measurements (cm) of: * Sternal Notch to Nipple * Nipple to Inframammary Fold (IMF) * Base Width (at point of breast take off from chest wall) * Nipple to nipple
Number of Adverse Events Will be Assessed Based on Frequency, Severity and Causality Data.
时间窗: 12 months
Safety will be evaluated by observation, assessment and recording of adverse events, if occur. Evaluations will be done immediately after treatment and at all follow-up visits. Each occurrence will be described in a table presenting data including severity (mild, moderate or severe), causality (relationship to the device or the treatment), treatment and resolution. Data will be summarized and adverse event significance will be considered based on combination of the above listed items.
次要结局
未报告次要终点